Retham Raises $1.5M for Faster HIT Diagnostics

HIT testing has a supply-chain problem hidden inside a medical decision. A functional assay may depend on fresh donor platelets and specialized laboratory execution, even when clinicians need an answer quickly.

Retham Technologies has announced the initial close of a $1.5M Seed financing to change that operating reality. Talents Fund led the September 15, 2026 round, with Golden Angels Investors and Milwaukee Venture Partners participating. The capital will support clinical validation, FDA 510(k) clearance activities, manufacturing scale-up, and commercial readiness for HITDx, Retham's in-development functional diagnostic assay for heparin-induced thrombocytopenia.

The financing matters because Retham is not only developing another test for a difficult condition. The Milwaukee-area company is trying to standardize the biological input that keeps functional HIT testing concentrated in specialized laboratories. If cryopreserved platelets can retain the required performance through validation and scaled manufacturing, the location of the test could move closer to the treatment decision.

What Retham announced

Retham called the financing the initial close of a $1.5M Seed round. Its September 15 announcement names Talents Fund as lead investor and Golden Angels Investors and Milwaukee Venture Partners as participants. Retham says the round complements $4.8M in NIH and National Heart, Lung, and Blood Institute Small Business Innovation Research support, including a recent $2.8M Phase IIB award.

The public capital record needs one qualification. A Form D filed September 11 described a $1.5M Rule 506(b) equity offering with $1.06M sold, $440K remaining, 6 investors, and a first sale on August 28. That filing predates Retham's announcement by 4 days. The clean reading is that the filing captured an earlier point in the same financing and the company later announced the $1.5M initial close. The full close amount is therefore a company-announced figure, not an amount the September 11 filing independently showed as sold.

No valuation, investor ownership, check sizes, financing-related board changes, or detailed tranche terms were disclosed. Those omissions matter less than keeping the transaction accounting honest. A small diagnostic company can have several kinds of capital moving at once, and Retham's federal awards are non-dilutive support, not part of the Seed round.

Why HITDx focuses on the platelet

Heparin-induced thrombocytopenia is an immune adverse reaction to heparin. The American Society of Hematology describes HIT as prothrombotic and says one-third to one-half of cases are complicated by thrombosis, which can threaten a limb or a life.

The diagnostic path typically combines clinical assessment with laboratory testing. Immunoassays detect antibodies associated with HIT. Functional assays test whether antibodies can activate platelets, which addresses the mechanism more directly. Access is the complication. Functional tests can require fresh donor platelets, specialized personnel, and reference-laboratory workflows that are difficult to reproduce across ordinary hospital laboratories.

HITDx is designed around long-term-stable, responsive platelets. Retham says the assay could allow hospital and clinical laboratories to perform functional HIT testing without sourcing fresh donor platelets for every run. That is still a development claim. HITDx has not been described as FDA-cleared or commercially available, and the financing is explicitly intended to fund the evidence and operating systems required to move it toward that point.

From research reagent to regulated diagnostic

Retham has already taken a related platelet technology into a narrower market. In July, the company launched Retham Cryoplatelets for Research Use Only and named Prolytix as distributor. Researchers can use the product across platelet-function assays, drug screening, thrombin-generation testing, and assay development, according to the companies.

That launch gives Retham commercial experience with stabilized platelets, production, distribution, and laboratory users. It does not establish HITDx's clinical performance, regulatory clearance, or routine hospital adoption. Research reagents and regulated diagnostics live under different evidence and quality obligations. The value of the RUO route is that it puts the underlying reagent into real laboratories while the clinical program advances on its own track.

The NIH RePORTER record verifies federal support for development of a functional HIT in vitro diagnostic and identifies co-founder Curtis Jones as the project leader. Retham says co-founders Anand Padmanabhan and Curtis Jones created the cryopreserved platelet technology and that core intellectual property is exclusively licensed from Mayo Clinic. The current financing announcement identifies Anand Padmanabhan as Chief Medical Officer and Curtis Jones as VP, Research & Innovation. Steven Visuri serves as CEO.

The investors are funding a handoff

Talents Fund describes itself as a seed-stage life-science investor focused on companies outside the largest coastal venture hubs. Retham fits that thesis unusually well. The company is based in Wauwatosa, built around clinician-scientist and laboratory expertise, supported by federal research funding, and backed by 2 Wisconsin investment groups alongside the lead.

The capital is now assigned to the work between a promising assay design and a repeatable clinical product. Clinical validation must show how HITDx performs in the intended setting. The FDA process will determine whether the evidence supports clearance. Manufacturing has to preserve platelet responsiveness across lots, storage, shipping, and routine use. Commercial readiness has to turn those controls into a workflow laboratories can buy, train on, and trust.

That sequence is where many diagnostic stories become less cinematic and more consequential. A discovery can be impressive in a research setting. A regulated diagnostic must produce dependable answers under the ordinary pressure of hospital operations, where an urgent sample is not interested in how elegant the original science looked.

What the Seed round changes

Retham now has company-announced equity capital alongside years of non-dilutive research support. That mix lets the business keep advancing the science while building the quality, regulatory, manufacturing, and commercial capabilities that grant-funded research alone does not automatically create.

The unresolved questions are concrete. Retham has not disclosed an FDA submission date, validation design, performance thresholds, manufacturing partner, pricing, reimbursement strategy, revenue, customer count, or HITDx launch timeline. Investors also did not disclose valuation or ownership. Those are not footnotes to invent around; they are the next record the company must build.

The larger opportunity is to make a specialist functional test operationally ordinary. Retham's founders began with a platelet problem. The Seed round gives the company room to prove that preserving the platelet can also preserve the diagnostic value as HITDx moves from controlled development into the clinical, regulatory, and manufacturing systems that will decide where the test can be used.